ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug pumitamig takes on nivolumab in stomach cancer showdown
Disease control Recruiting nowThis study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…
Matched conditions: ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to shrink tough stomach cancers
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is…
Matched conditions: ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC